Baseline clinical characteristics
| Placebo (n=3) | Clozapine (n=3) | Risperidone (n=3) | |
| % Female (n) | 67 (2) | 67 (2) | 100 (3) |
| Age (years) | 58 (12) | 57 (6) | 57 (9) |
| Bodyweight (kg) | 75.8 (21.6) | 89.4 (10.9) | 86.3 (26.6) |
| BMI (kg/m2) | 28.4 (3.7) | 30.8 (2.4) | 33.6 (7.9) |
| EDSS (±SD) | 6.3 (0.3) | 6.2 (0.6) | 6.2 (0.6) |
| FSS (±SD) | 6.4 (0.4) | 4.2 (1.5) | 6.3 (0.8) |
| MSFC (±SD) | −1.41 (1.2) | −0.91 (0.2) | −0.76 (1.1) |
| hsCRP (±SD) | 3 (0) | 4 (1) | 5.7 (2.3) |
| TropT (±SD) | 11.3 (4.7) | 7.3 (4.0) | 5.3 (0.6) |
| Prolactin (±SD) | 194 (78) | 203 (87) | 200 (88) |
BMI, body mass index; EDSS, Expanded Disability Status Scale; FSS, fatigue severity scale; hsCRP, high-sensitivity C reactive protein; MSFC, Multiple Sclerosis Functional Composite; TropT, troponin-T.